CFMS:NSD-Conformis, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.40

Change

+0.01 (+0.72)%

Market Cap

USD 0.12B

Volume

4.10M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia. Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Company Website : http://www.conformis.com

Address : 600 Technology Park Drive, Billerica, MA, United States, 01821

Employees : 262

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.63

52 Week High : 1.47

Short Ratio : 1.94

52 Week Low : 0.50

Shorted Shares : 5,001,398

200 Day Moving Average : 0.74

Shorted Shares Previous Month : 483,108

50 Day Moving Average : 0.76

Shares Held By Insiders : 71.06%

Short Percentage : 6.00%

Shares Held by Institutions : 30.64%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-9.73 (-1.79%)

 USD42.88B 24.75 105.78
PODD Insulet Corporation

-0.32 (-0.11%)

 USD19.16B 660.50 158.47
ABMD Abiomed, Inc

-0.66 (-0.19%)

 USD15.75B 76.61 57.33
LVGO Livongo Health, Inc

N/A

 USD14.20B N/A N/A
BRKR Bruker Corporation

-0.02 (-0.03%)

 USD9.32B 60.14 28.92
TNDM Tandem Diabetes Care, Inc

+4.18 (+4.43%)

 USD5.87B N/A N/A
IART Integra LifeSciences Holdings ..

-0.08 (-0.12%)

 USD5.85B 105.12 25.49
SWAV ShockWave Medical, Inc

-1.51 (-1.15%)

 USD4.50B N/A N/A
SDC SmileDirectClub, Inc

+0.26 (+2.36%)

 USD4.17B N/A N/A
WMGI Wright Medical Group N.V

N/A

 USD3.90B N/A 50.67

ETFs Containing CFMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 112.12% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 112.12% 96% A 98% A+
Trailing 12 Months  
Capital Gain 37.25% 59% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.25% 59% F 68% D+
Trailing 5 Years  
Capital Gain -87.88% 20% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.88% 18% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -13.47% 21% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.47% 21% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 95.89% 15% F 11% F
Risk Adjusted Return -14.05% 32% F 27% F
Market Capitalization 0.12B 34% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.71 68% D+ 42% F
Price / Cash Flow Ratio -42.09 90% A- 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -119.39% 26% F 9% F
Return on Invested Capital -57.90% 33% F 17% F
Return on Assets -18.73% 36% F 20% F
Debt to Equity Ratio 120.05% 22% F 18% F
Technical Ratios  
Short Ratio 1.94 68% D+ 60% D-
Short Percent 5.95% 39% F 35% F
Beta 1.63 29% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.